BioNTech and Bristol Myers Squibb collaborate on bispecific antibody for solid tumours

Ella Day | June 6, 2025 | News story | Research and Development BioNTech, Oncology, bispecific antibody treatment, bristol myers squibb, oncology, partnership 

BioNTech and Bristol Myers Squibb (BMS) have entered a partnership to collaboratively develop and commercialise BNT327, BioNTech’s bispecific antibody, to treat multiple solid tumour types.

BNT327 targets two established immuno-oncology pathways, PD-L1 and VEGF-A, to enhance tumour targeting and modulate the tumour microenvironment. It is currently in phase 3 trials for small cell and non-small cell lung cancer, and a further investigation in triple-negative breast cancer is expected to begin later this year.

The companies will jointly lead a comprehensive development programme, including monotherapy and combination strategies. More than 20 trials are ongoing or planned, with over 1,000 patients treated to date.

Advertisement

“We believe BNT327 has the potential to become a foundational immuno-oncology backbone, moving beyond single-mechanism checkpoint inhibitors and expanding into multiple solid-tumour indications,” said Ugur Sahin, chief executive officer of BioNTech. “Our collaboration with BMS, aims to accelerate BNT327’s development to fully realise its potential.”

Christopher Boerner, chief executive officer of BMS, added: “We are impressed by the innovation that BioNTech has achieved to date, and we look forward to partnering to accelerate existing clinical trials and time to market, while expanding the number of potential indications.”

Ella Day

6/6/25

Related Content

Rethinking oncology trial endpoints with generalised pairwise comparisons

For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

partnership

Landmark Bio and Mass General Brigham partner to accelerate translational CGT therapies

Landmark Bio and Mass General Brigham in the US have entered a new strategic collaboration …

drug-trials

Pharma&’s ovarian cancer therapy approved for use by NHS Scotland

Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …

The Gateway to Local Adoption Series

Latest content